Antwort schreiben 
Warnung vor Fluorchinolonen (Ciprofloxacin, Levofloxacin, usw)
Verfasser Nachricht
Sunflower Offline
Posting Freak
*****

Beiträge: 1.933
Registriert seit: Apr 2013
Thanks: 1589
Given 1962 thank(s) in 845 post(s)
Beitrag #2
RE: WARNUNG VOR FLUORQUINOLONE (Ciprofloxacin, Levofloxacin, usw)
Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network

By: Kamaljeet Kaur et al
February 21, 2016

http://www.oncologypractice.com/specialt...d-shared=1


Zitat:Methods 5 groups of C57BL/6 mice receiving the antibiotic ciprofoxacin in 10-mg increments (10 mg/kg-50 mg/kg) and 1 group of control mice were evaluated.

The Southern Network on Adverse Reactions (SONAR) and a social network of FQ-treated persons with long-term NP toxicity (the Floxed Network) conducted a web-based survey. The clinical toxicity manifestations reported by 94 respondents to the web-based survey of persons who had received 1 or more doses of an FQ prescribed for any indication (generally at FDA-approved dosages) and who subsequently experienced possible adverse drug reactions were compared with adverse event information included on the product label for levofoxacin and with FQ-associated adverse events reported to the FDA’s MedWatch program.


Results Mice treated with ciprofoxacin had lower grip strengths, reduced balance, and depressive behavior compared with the controls. For the survey, 93 of 94 respondents reported FQ-associated events including anxiety, depression, insomnia, panic attacks, clouded thinking, depersonalization, suicidal thoughts, psychosis, nightmares, and impaired memory beginning within days of FQ initiation or days to months of FQ discontinuation. The FDA Adverse Event Reporting System (FAERS) included 210,705 adverse events and 2,991 fatalities for FQs. Levofoxacin and ciprofoxacin toxicities were neurologic (30% and 26%, respectively), tendon damage (8% and 6%), and psychiatric (10% and 2%). In 2013, an FDA safety review reported that FQs affect mammalian topoisomerase II, especially in mitochondria. In 2013 and 2014, SONAR fled citizen petitions requesting black box revisions identifying neuropsychiatric toxicities and mitochrondrial toxicity as serious levofoxacin-associated adverse drug reactions. In 2015, FDA advisors recommended that FQ product labels be revised to include information about this newly identified disability syndrome termed “FQ-associated disability” (FQAD).

Gute Besserung und liebe Grüsse
Sunflower


Lyme-Borreliose seit 2008

Seit Mai 2014 Mitglied beim OnLyme-Aktion.org Verein
03.03.2016 20:39
Alle Beiträge dieses Benutzers finden Diese Nachricht in einer Antwort zitieren
 Thanks given by: Nimrod , Amrei
Antwort schreiben 


Nachrichten in diesem Thema
RE: WARNUNG VOR FLUORQUINOLONE (Ciprofloxacin, Levofloxacin, usw) - Sunflower - 03.03.2016 20:39

Gehe zu:


Benutzer, die gerade dieses Thema anschauen: 1 Gast/Gäste